Cargando…

Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia

[Image: see text] Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative neoplasm of early childhood with a poor survival rate, thus there is a requirement for improved treatment strategies. Induced pluripotent stem cells offer the ability to model disease and develop new treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pearson, Stella, Guo, Baoqiang, Pierce, Andrew, Azadbakht, Narges, Brazzatti, Julie A., Patassini, Stefano, Mulero-Navarro, Sonia, Meyer, Stefan, Flotho, Christian, Gelb, Bruce D., Whetton, Anthony D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2019
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942217/ https://www.ncbi.nlm.nih.gov/pubmed/31657576 http://dx.doi.org/10.1021/acs.jproteome.9b00495

Ejemplares similares

Induced Pluripotent Stem Cells to Model Juvenile Myelomonocytic Leukemia: New Perspectives for Preclinical Research
por: Wehbe, Zeinab, et al.
Publicado: (2021)

Current Treatment of Juvenile Myelomonocytic Leukemia
por: Mayerhofer, Christina, et al.
Publicado: (2021)

CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia
por: Fluhr, Silvia, et al.
Publicado: (2016)

Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia
por: Stieglitz, Elliot, et al.
Publicado: (2017)

Generation of a mouse SWATH-MS spectral library to quantify 10148 proteins involved in cell reprogramming
por: Ulanga, Uxue, et al.
Publicado: (2021)

P1000: JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) INHIBITS T CELL PROLIFERATION VIA THE ECTONUCLEOTIDASE CD39 AND THE PURINERGIC NETWORK
por: Rajak, Jovana, et al.
Publicado: (2023)

The Genomic Landscape of Juvenile Myelomonocytic Leukemia
por: Stieglitz, Elliot, et al.
Publicado: (2015)

Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia
por: Hofmans, Mattias, et al.
Publicado: (2021)

Molecular Targets for the Treatment of Juvenile Myelomonocytic Leukemia
por: Liu, Xiaoling, et al.
Publicado: (2012)

CircRNAs Dysregulated in Juvenile Myelomonocytic Leukemia: CircMCTP1 Stands Out
por: Dal Molin, Anna, et al.
Publicado: (2021)

Mutation-Specific Signaling Profiles and Kinase Inhibitor Sensitivities of Juvenile Myelomonocytic Leukemia Revealed by Induced Pluripotent Stem Cells
por: Tasian, Sarah K, et al.
Publicado: (2018)

Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia
por: Fiñana, Claudia, et al.
Publicado: (2022)

Molecular and phenotypic diversity of CBLmutated juvenile myelomonocytic leukemia
por: Hecht, Anna, et al.
Publicado: (2020)

Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia
por: Niemeyer, Charlotte M., et al.
Publicado: (2010)

RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia
por: Lipka, Daniel B., et al.
Publicado: (2017)

Novel splicing-factor mutations in juvenile myelomonocytic leukemia
por: Takita, J, et al.
Publicado: (2012)

P1072: NATURAL HISTORY OF JUVENILE MYELOMONOCYTIC LEUKEMIA
por: Yang, W., et al.
Publicado: (2022)

Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches
por: Pearson, S, et al.
Publicado: (2017)

Erratum: Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches
por: Pearson, S, et al.
Publicado: (2017)

Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia
por: Marcu, Andra, et al.
Publicado: (2020)

Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia
por: Louka, Eleni, et al.
Publicado: (2021)

Clinical and molecular features of CBL-mutated juvenile myelomonocytic leukemia
por: Yoshida, Taro, et al.
Publicado: (2023)

Deficiency of CREB and over expression of miR-183 in juvenile myelomonocytic leukemia
por: Liu, Y L, et al.
Publicado: (2013)

Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples
por: Behnert, Astrid, et al.
Publicado: (2021)

Gene module analysis of juvenile myelomonocytic leukemia and screening of anticancer drugs
por: Zhao, Wencheng, et al.
Publicado: (2018)

Combination of curaxin and tyrosine kinase inhibitors display enhanced killing of primitive Chronic Myeloid Leukaemia cells
por: Pearson, Stella, et al.
Publicado: (2022)

MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment
por: Leoncini, Pier Paolo, et al.
Publicado: (2016)

Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features
por: Tüfekçi, Özlem, et al.
Publicado: (2015)

Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia
por: Sakaguchi, Hirotoshi, et al.
Publicado: (2015)

Juvenile Myelomonocytic Leukemia in Turkey: A Retrospective Analysis of Sixty-five Patients
por: Tüfekçi, Özlem, et al.
Publicado: (2018)

Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report
por: Upadhyay, Shivani Y., et al.
Publicado: (2017)

Parvovirus B19 Infection Mimicking Juvenile Myelomonocytic Leukemia in an Immunocompetent Child
por: Mathew, Aji, et al.
Publicado: (2020)

Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia
por: Kitazawa, Hironobu, et al.
Publicado: (2021)

P985: CLL-1 IS AN ADOPTIVE IMMUNOTHERAPY TARGET IN JUVENILE MYELOMONOCYTIC LEUKEMIA
por: Huebner, Juwita, et al.
Publicado: (2023)

Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia
por: Hasegawa, D, et al.
Publicado: (2013)

Prolonged Pediatric Extracorporeal Membrane Oxygenation Support with Cardiopulmonary Failure in Juvenile Myelomonocytic Leukemia
por: Bartkevics, Maris, et al.
Publicado: (2020)

Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group
por: Bresolin, Silvia, et al.
Publicado: (2016)

S206: ONCO-FETAL REPROGRAMMING DRIVES HIGH-RISK JUVENILE MYELOMONOCYTIC LEUKEMIA, WHICH CAN BE TARGETED BY ANTI-CD52 TREATMENT
por: Hartmann, Mark, et al.
Publicado: (2023)

Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL
por: Gagne, Alyssa L., et al.
Publicado: (2018)

Leukemia cutis in a child with juvenile myelomonocytic leukemia presenting with Sweet syndrome–like lesions and a history of multiple juvenile xanthogranulomas
por: Quek, Chrystie Wan Ning, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_in7dujdn6irvlkoj4c07ri9ukh